Medication info

Jensigamet Sustained Release Tablet 10/500 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Anhydrous Lactose Mixture›15.27mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Albozen Korea Co., Ltd.
Appearance
Pink, double convex, oval-shaped sustained release film-coated tablet
Packaging
30 tablets/box [(6 tablets/PTP) * 5], 30 tablets/bottle
Approval status
Active

MFDS item code 202301897 · Approved 2023.06.21

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, given as 2 tablets of 5mg/1000mg. Patients with no previous experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no previous experience with antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. For patients switching from concomitant therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the current doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because changes may cause alterations in glycemic control, any changes in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must not be crushed, cut, or chewed. Occasionally, inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to be decreased in elderly patients, this medicine should be used with caution as age increases (see Precautions, 9. Use in elderly patients).

Ingredients

Manufacturer
Albozen Korea Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • blood sugar control issues
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication helps control blood sugar levels in adult patients with type 2 diabetes when administered in combination with dapagliflozin and metformin alongside dietary and exercise regimens. It is particularly important to consult a specialist to assess the impact of this medication on cardiovascular events in patients with type 2 diabetes who have difficulty controlling their blood sugar and also have cardiovascular disease or related risk factors. Therefore, this medication assists in the control of blood sugar levels and the management of cardiovascular health in type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, given as 2 tablets of 5mg/1000mg. Patients with no previous experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no previous experience with antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. For patients switching from concomitant therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the current doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because changes may cause alterations in glycemic control, any changes in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must not be crushed, cut, or chewed. Occasionally, inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to be decreased in elderly patients, this medicine should be used with caution as age increases (see Precautions, 9. Use in elderly patients).

Precautions

This medication contains metformin hydrochloride and dapagliflozin for the treatment of diabetes. Renal function is crucial when taking this medication, and patients with severely impaired renal function should not take it. Additionally, this medication should be avoided in acute conditions such as dehydration, severe infections, cardiovascular problems, or acute myocardial infarction. It is not safe to use this medication in pregnant or breastfeeding women. Since this medication contains lactose, patients with lactose intolerance should not take it. While taking this medication, there is a rare but serious risk of lactic acidosis; if symptoms such as malaise or difficulty breathing occur, immediate consultation with a physician is necessary. Caution is required when taking this medication with insulin or sulfonylureas due to the risk of hypoglycemia; insulin dosages should be adjusted as needed. This medication may cause reduced fluid volume or low blood pressure; therefore, elderly patients or those on diuretics should exercise particular caution and regularly monitor their blood pressure and renal function. Additionally, this medication may increase the risk of genital and urinary tract infections, necessitating prompt treatment if infection symptoms appear. Before undergoing surgery or radiologic examinations, this medication should be discontinued for a certain period, and it should be restarted only after renal function is confirmed to be normal post-examination. Since vitamin B12 levels may decrease, regular checks for vitamin B12 levels are advisable during prolonged use. Excessive alcohol consumption should be avoided as it increases the risk of side effects from this medication. This medication may lead to blood sugar control failures, so consult a physician for appropriate measures during infections or stressful situations. No safety and efficacy have been established for this medication in children; hence, it should not be used in this population. While taking this medication, dizziness may occur when driving or operating machinery, so caution is warranted. Finally, this medication should be kept out of reach of children and stored in its original container for safety.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 86 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • pruritus of the vulva
  • genital pruritus
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • increased blood creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burns
  • wrist fracture
  • gastrointestinal stromal tumors
  • malignant lung neoplasms
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremors
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarthritis
  • tendinitis
  • trigger finger
  • myasthenia
  • fatigue
  • peripheral edema
  • swelling
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasions
  • benign prostatic hyperplasia
  • pruritus
  • palpitations
  • insomnia
  • Type 2a hyperlipidemia
  • sensorineural hearing loss
  • acute cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air and moisture exposure, at room temperature between 1 and 30 degrees Celsius. This storage will help maintain the medication’s efficacy over time.

Appearance and packaging

Appearance

Pink, double convex, oval-shaped sustained release film-coated tablet

Package unit

30 tablets/box [(6 tablets/PTP) * 5], 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.